Placental alpha-microglobulin-1 and combined traditional diagnostic test: a cost-benefit analysis

Our cost-benefit analysis provides the economic evidence for the adoption of PAMG-1 in diagnosing preterm premature rupture of membranes in uncertain presentations and when CTDT is equivocal at 34 to <37 weeks' gestation.